CPHI: Trends shaping pharma’s path
This week CPHI 2023 will unite industry leaders, innovators, and start-ups to explore sustainable solutions, cutting-edge technologies, and collaborative partnerships.
ADVERTISEMENT
About Uta Mommert
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 287 entries already.
Entries by Uta Mommert
Breakthrough in microtia treatment
Researchers developed an innovative ear transplant method to treat microtia using tissue-engineered human skin and bioprinted cartilage.
Joining forces for mRNA breakthrough
Dyadic International Inc. and bYoRNA SAS partnered to advance innovative bioproduction technologies for scaling up the production of therapeutic mRNA from C1-Cells.
SeaBeLife secures €1.2m in funding
Biotech company, specialising in cell necrosis prevention, has announced a successful funding round, securing €1.2m in additional seed funding.
Crucible Therapeutics spins out with £5m
University of Sheffield spinout gets £5m for gene therapies targeting ALS and FTD, advancing towards clinical trials.
Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica’s proposed acquisition of ABL Europe from Institut Mérieux, at a consideration of €15m propels global leadership in cell and gene therapy.
Radiotherapy R&D partnership
Orano Med SAS and Orbit Discovery Ltd announced a collaboration to develop Peptide Receptor Radionuclide Therapies for cancer cells and develop novel radiopharmaceuticals.
BioInnovation Institute Boosts Six Life Science Companies
Non-profit foundation BioInnovation Institute (BII) has unveiled its latest commitment to driving innovation and growth within the life science sector. Six promising companies will receive crucial financial support through BII’s Venture House programme.
UK invests in biopharma manufacturers
The UK is making €15m investment in its biopharmaceutical manufacturing industry via its national innovation agency Innovate UK. It is part of the country’s larger push to support the domestic Life Sciences.
Oxford Biomedica expands agreement with Cabaletta Bio
British CDMO Oxford Biomedica plc announces the expansion of its License and Supply Agreement with cell therapy specialist Cabaletta Bio, Inc. The new agreements adds CD19 as a new target – it originally covered Cabaletta Bio’s lead product, DSG3-CAART.